April 02, 2012 at 13:01 PM EDT
Drug Trial Failure For Keryx And Aeterna

Keryx Biopharmaceuticals Inc. (Nasdaq: KERX) and Aeterna Zentaris (Nasdaq: AEZS) reported that their colorectal cancer treatment Perifosine failed a Phase 3 clinical trial. Shares of Keryx plummeted $3.30 to $1.68 while Aeterna stock plunged $1.39 to $0.75.



Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here